Relmada Therapeutics (RLMD) Common Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Common Equity for 15 consecutive years, with $218.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 874.72% year-over-year to $218.7 million; the TTM figure through Mar 2026 stood at $218.7 million (up 874.72% YoY), while the FY2025 annual figure was $86.5 million, up 143.55% from the prior year.
• Common Equity climbed to $218.7 million in Q1 2026 per RLMD's latest filing, from $86.5 million in the prior quarter.
• Across five years, Common Equity topped out at $218.7 million in Q1 2026 and bottomed at $9.5 million in Q3 2025.
• Historically, Common Equity has averaged $100.4 million across 5 years, with a median of $86.5 million in 2025.
• Annual changes were most pronounced in 2025 — Common Equity tumbled 80.12% — and 2026, when it soared 874.72%.
• Relmada Therapeutics' Common Equity stood at $140.4 million in 2022, then plunged by 39.22% to $85.4 million in 2023, then plunged by 58.38% to $35.5 million in 2024, then surged by 143.55% to $86.5 million in 2025, then jumped by 152.83% to $218.7 million in 2026.
• Business Quant data shows RLMD's Common Equity at $218.7 million in Q1 2026, $86.5 million in Q4 2025, and $9.5 million in Q3 2025.